Akari Therapeutics to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference

Rhea-AI Summary

Akari Therapeutics (Nasdaq: AKTX), a biotechnology firm, announced participation in the Cantor Medical and Aesthetic Dermatology Conference in Miami on December 7-8, 2022. President and CEO Rachelle Jacques will join an ophthalmology panel on December 8, discussing 'Vision for the Future: Dry AMD, Other Greenfield Opportunities, and Late-Stage Stories to Shake Things Up.' The management team will also conduct 1:1 investor meetings to address their pre-clinical program for long-acting PAS-nomacopan in geographic atrophy (GA). Akari's investigational drug, nomacopan, targets autoimmune diseases.

NEW YORK and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will participate in the investor-focused Cantor Medical and Aesthetic Dermatology, Ophthalmology and Medtech/Diagnostic Conference taking place in Miami December 7-8, 2022. Akari President and CEO Rachelle Jacques will take part in an ophthalmology panel on December 8 at 1:45 pm ET, Vision for the Future: Dry AMD, Other Greenfield Opportunities, and Late-Stage Stories to Shake Things Up. The Akari management team also will attend 1:1 investor meetings at the conference to discuss progress in the promising pre-clinical program that is investigating long-acting PAS-nomacopan in geographic atrophy (GA).

About Akari Therapeutics
Akari Therapeutics, plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari's lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Akari's pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). Akari has been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the FDA for nomacopan for the treatment of pediatric HSCT-TMA. Akari’s pipeline also includes pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). For more information about Akari, please visit akaritx.com.

Investor Contact:
Mike Moyer
LifeSci Advisors
(617) 308-4306
mmoyer@lifesciadvisors.com

Media Contact:
Eliza Schleifstein
Schleifstein PR   
(917) 763-8106
eliza@schleifsteinpr.com

FAQ

What event is Akari Therapeutics attending in December 2022?

Akari Therapeutics will participate in the Cantor Medical and Aesthetic Dermatology Conference on December 7-8, 2022.

When is the ophthalmology panel featuring Akari's CEO?

The ophthalmology panel with CEO Rachelle Jacques is scheduled for December 8, 2022, at 1:45 pm ET.

What is Akari Therapeutics' focus at the conference?

Akari Therapeutics will focus on discussing their pre-clinical program for long-acting PAS-nomacopan in geographic atrophy.

What is nomacopan and its relevance to Akari Therapeutics?

Nomacopan is Akari's investigational drug aimed at treating autoimmune diseases, currently in a Phase 3 trial for pediatric HSCT-TMA.

What designations has Akari received for nomacopan?

Nomacopan has been granted Orphan Drug, Fast Track, and Rare Pediatric Disease designations by the FDA.